<DOC>
	<DOCNO>NCT00353678</DOCNO>
	<brief_summary>The purpose study find best possible ( optimal ) dose ( effect versus adverse event ) YM150 prevent risk blood clot formation schedule hip replacement surgery .</brief_summary>
	<brief_title>Factor Xa Inhibitor YM150 Prevention Blood Clot Formation Veins After Scheduled Hip Replacement ( ONYX-2 )</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Darexaban</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Scheduled elective primary hip replacement Age 18 year Written inform consent obtain Documented history consider increase risk venous thromboembolism Subjects consider increase risk bleed Surgery plan contralateral hip time within 10 week enrolment Concomitant use anticoagulants/ antiplatelet agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Hip replacement</keyword>
	<keyword>Arthroplasty</keyword>
	<keyword>Prevention</keyword>
	<keyword>Thromboembolism</keyword>
	<keyword>Treatment outcome</keyword>
	<keyword>Arthroplasty , replacement , hip</keyword>
</DOC>